Company: AEMD
Filing Date: 2025-07-25
Form Type: DRS
Source: 0001683168-25-005397
Chunk: 46

Company: AETHLON MEDICAL INC
Filing Date: 2025-07-25
Form: DRS
Chunk 46
---
 that
our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus
by these cautionary statements.

Except as required by law,
we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially
from those anticipated in any forward-looking statements, whether as a result of new information, future events or otherwise.

This prospectus also refers
to estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about
our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.
In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate
are necessarily subject to a high degree of uncertainty and risk.

| 24 |

<div align='center'>USE OF PROCEEDS</div>

Inducement Offering

The Selling Securityholders
will be offering the shares of common stock underlying the Inducement Warrants being covered by this prospectus at prevailing market prices
or privately negotiated prices. We will not receive any proceeds from the sale of shares of common stock offered by the Selling Securityholder
under this prospectus. However, we will receive the proceeds of any cash exercise of the Inducement Warrants. If all of the Inducement
Warrants were exercised for cash, we would receive aggregate proceeds of approximately $4,634,500.Since the Inducement Warrants are currently
worth less than what an investor would pay per share, the Selling Securityholder is unlikely to exercise. Cash proceeds associated with
the exercise(s) of the Inducement Warrants, if any, are dependent on the Company’s stock price at the time of exercise. If we receive
proceeds, we currently intend to use the proceeds for general corporate purposes.

Company Offering

We estimate that the net proceeds
of the Company Offering will be approximately $ million, based
on the assumed combined public offering price of $ per share and
accompanying warrant (the last reported sale price of our common stock on The Nasdaq Capital Market on July ,
2025), after deducting the placement agent fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from
the exercise of the warrants. Each $0.10 increase (decrease) in the assumed combined public offering price of $ per
share and accompanying warrant would increase (